Premium
IMPROVED OUTCOMES IN PATIENTS (PTS) WITH BCL2‐POSITIVE DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL) TREATED WITH VENETOCLAX (VEN) PLUS R‐CHOP: RESULTS FROM THE PHASE 2 CAVALLI STUDY
Author(s) -
Morschhauser F.,
Flinn I.W.,
Gasiorowski R.,
Illés Á.,
Feugier P.,
Greil R.,
Johnson N.A.,
Larouche J.,
Lugtenburg P.J.,
Patti C.,
Salles G.,
Trněný M.,
Vos S.,
Mir F.,
Kornacker M.,
Punnoose E.A.,
Samineni D.,
SzaferGlusman E.,
Petrich A.,
Sinha A.,
Spielewoy N.,
Humphrey K.,
Bazeos A.,
Zelenetz A.D.
Publication year - 2019
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.95_2629
Subject(s) - medicine , clinical endpoint , diffuse large b cell lymphoma , chop , rituximab , ven , oncology , gastroenterology , venetoclax , regimen , lymphoma , randomized controlled trial , chronic lymphocytic leukemia , leukemia , computer security , computer science